One out of every 12 men has prostate cancer! The solution is early detection
Prostate cancer is one of the most common types of cancer in the male population. According to 2012 statistics; While 1 million cases of prostate cancer were detected worldwide, death due to prostate cancer was seen in 300 thousand people. These results place prostate cancer in the second place in cancer-related deaths after lung cancer. Although the statistical data for our country is not clear, according to the research conducted by the Urooncology Association; Prostate cancer is the most common solid organ tumor in our male population. Recent information indicates that one out of 12 men in our country has prostate cancer.
New Methods Allow More Accurate Diagnosis
Vice President of Urooncology Association and Gazi University Faculty of Medicine Department of Urology Professor. Dr. Sinan Sözen shared the following information, stating that prostate examination and PSA test performed by urologists starting from the age of 40 are recommended for men in the risk group, especially those with a family history of prostate cancer, for early diagnosis, while these controls are recommended to begin at the age of 50 in the population who are not in the risk group. In addition to our routine tests, patients with suspected multiparametric prostate MRI are performed. This particular prostate MRI evaluates whether there is a suspicious area for cancer in the prostate gland.
If any, the sections with suspected cancer can be marked and then placed on ultrasound with the help of special software.
The name of this method is Prostate MR Fusion Biopsy. Unfortunately, 20-25% of life-threatening clinically important prostate cancer could be missed with the old method. This means not being able to diagnose a patient and bypassing a vitally important cancer. Another aspect of the event was that we could unnecessarily diagnose ‘clinically insignificant cancers’, a concept specific to prostate cancer. Unfortunately, this rate could reach 40-50%. This means unnecessary surgery, unnecessary treatment, unnecessary cost. The new method largely eliminates such disadvantages.”
Stating that prostate cancer is a disease that needs to be treated with a multidisciplinary approach, like many other types of cancer, Sözen said, “Urooncologists, medical oncologists, radiation oncologists, nuclear medicine specialists, radiologists, pathologists, molecular geneticists are included in this multidisciplinary team. It is the primary duty of the Urooncology Association, starting from raising the awareness of prostate cancer in our country, to ensure that these issues are discussed in scientific fields, and to encourage and support scientific studies.”
It will be organized by the Urooncology Association for the first time in Turkey in cooperation with the American Society of Clinical Oncology.
Stating that the Urooncology Association has been trying to fulfill its duties in this field since its establishment in 1999, Prof. Dr. Sözen gave the following information: “As a first in Turkey in 2017, the original slide containing the main topics of the ASCO Direct Highlight of GU 2017 congress, one of the most important multidisciplinary urooncology congresses in the world, in cooperation with the ASCO (American Society of Clinical Oncology) – Urooncology Association. The meeting, which will be held using the sets, will be held by the Urooncology Association on 5-6 May 2017 at the Ankara Hilton Hotel.
In our meeting, which is also supported by the Cancer Control Foundation, it is aimed to evaluate the most common cancers such as prostate cancer, kidney tumor, bladder and testicular cancer with the latest scientific information by all branches from a world perspective. The purpose of all these meetings is to unite this multidisciplinary team around the same goal and to increase our ability to use current science for the benefit of our patients.